证券研究报告 | 北交所定期报告 | | --- | hyzqdatemark 2026 年 03 月 01 日 证券分析师 赵昊 SAC：S1350524110004 zhaohao@huayuanstock.com 王宇璇 SAC：S1350525050003 wangyuxuan@huayuanstock.com 国内多个氨基酸品种价格上涨，关注氨基酸原料药"小巨人"无锡晶海 ——北交所消费服务产业跟踪第五十三期（20260301） 投资要点： 中国氨基酸市场多个氨基酸品类主流报价上涨，欧洲市场多数品类维持小幅涨势。 联系人 根据秣宝网公众号（数据更新至 2026/2/27），目前国内蛋氨酸主流市场报价 18.8-19.2 元/kg，蛋氨酸市场主流厂家报价上调，有厂家停报停签，终端询单积极， 少量按需签单，秣宝网预计短期内蛋氨酸价格或略微上涨；目前国内苏氨酸市场主 流报价 7.4-7.8 元/kg，苏氨酸市场厂家报价上涨，出口报价也涨至 950-980 美元/ 吨，下游用户观望情绪浓厚，维持按需采买，秣宝网预计短期内苏氨酸价格或稳中 偏强；目前国内缬氨酸市场主流报价为 13.0-13.5 元/kg，缬氨 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company is expected to see a 46.39% year-on-year increase in net profit attributable to shareholders, with projected revenue of 406 million yuan for 2025 [4] - The core business segments are experiencing a recovery in demand, contributing to stable revenue and profit growth [4] - The company is actively expanding into new product categories and enhancing its overseas business presence [5] Financial Summary - Total revenue is projected to grow from 389 million yuan in 2023 to 662 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 23.7% [7] - Net profit attributable to shareholders is expected to increase from 53 million yuan in 2023 to 103 million yuan in 2027, with a significant growth rate of 18.4% in 2027 [7] - The company's gross margin is projected to stabilize around 30.6% from 2026 onwards [8] Business Development - The company has established a presence in overseas markets, with external sales accounting for approximately 56.88% of total revenue as of Q3 2025 [5] - New factories are in trial production, which will help address capacity constraints once regulatory approvals are obtained [5] - The company plans to diversify its product offerings beyond amino acids to include derivatives, functional peptides, and other innovative products [4]

Market Overview - The global amino acid market is projected to grow from $26.19 billion in 2021 to $49.42 billion by 2030, with a CAGR of 7.3%[2] - In 2023, China's amino acid market reached ¥43.635 billion, reflecting a year-on-year growth of 4.2%[2] - In 2020, China accounted for 32.23% of the global amino acid market, leading the world[2] Industry Dynamics - China's amino acid production is dominated by glutamic acid (42.06%) and lysine (36.80%) as of 2020[19] - The domestic amino acid industry has a complete supply chain, with applications in animal feed, food additives, pharmaceuticals, and fine chemicals[6] - The demand for high-value-added amino acids is increasing, with products like phenylalanine and isoleucine gaining traction[2] Company Spotlight - Wuxi Jinghai is recognized as a "little giant" in amino acid raw materials, focusing on branched-chain amino acids and other products[26] - In 2024, Wuxi Jinghai's revenue from amino acid raw materials is expected to constitute 57% of its total revenue[30] - The company has obtained a food production license, allowing it to expand its amino acid applications in the food sector[29] Market Performance - From July 21 to July 25, 2025, the median market cap change for North Exchange consumer service stocks was +1.68%, with 70% of companies experiencing an increase[37] - The median P/E ratio for North Exchange consumer service companies decreased from 58.6X to 57.1X during the same period[39] Investment and Expansion - Companies like Baixinglong are establishing subsidiaries in Italy and Hong Kong to enhance their international market presence[56] - The global raw material drug market is expected to reach $226.1 billion in 2024, growing at a rate of 5.3%[27]